Cargando…

Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer

In this phase-I trial, we evaluated the safety of S-1, a novel oral fluoropyrimidine anticancer agent, combined with external-beam radiotherapy (EBRT) to determine the maximum-tolerated dose and dose-limiting toxicity (DLT) in unresectable pancreatic cancer patients. Patients had histologically prov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shinchi, H, Maemura, K, Noma, H, Mataki, Y, Aikou, T, Takao, S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360168/ https://www.ncbi.nlm.nih.gov/pubmed/17437021 http://dx.doi.org/10.1038/sj.bjc.6603735

Ejemplares similares

Clinical significance of midkine expression in pancreatic head carcinoma
por: Maeda, S, et al.
Publicado: (2007)

CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer
por: Maeda, S, et al.
Publicado: (2008)

Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis
por: Mataki, Yuko, et al.
Publicado: (2021)

Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer()
por: Harada, Koji, et al.
Publicado: (2017)

Concurrent radiotherapy with oral fluoropyrimidine versus gemcitabine in locally advanced pancreatic cancer: a systematic review and meta-analysis
por: Yang, Yong-Feng, et al.
Publicado: (2015)

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer
por: Chadha, Awalpreet S., et al.
Publicado: (2016)

Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer
por: Arscott, William T., et al.
Publicado: (2021)

Pancreatic hamartoma: a case report and literature review
por: Matsushita, Daisuke, et al.
Publicado: (2016)

Successful treatment for severe pancreatitis with colonic perforation using video-assisted retroperitoneal debridement: A case report
por: Hozaka, Yuto, et al.
Publicado: (2018)

Gallbladder adenocarcinoma with sarcoid-like reaction in regional lymph nodes: report of a case
por: Kawasaki, Yota, et al.
Publicado: (2014)

A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer
por: Ikeda, M, et al.
Publicado: (2007)

Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer
por: Katsumata, N., et al.
Publicado: (2011)

Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma
por: Ohtsu, A, et al.
Publicado: (2000)

Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
por: Punt, C.J.A., et al.
Publicado: (2023)

Locally Advanced and Unresectable Cutaneous Squamous Cell Carcinoma: Outcomes of Concurrent Cetuximab and Radiotherapy
por: Samstein, Robert M., et al.
Publicado: (2014)

Icotinib With Concurrent Radiotherapy vs Radiotherapy Alone in Older Adults With Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Randomized Clinical Trial
por: Luo, Honglei, et al.
Publicado: (2020)

The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma
por: Okumura, H, et al.
Publicado: (2005)

Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience
por: Muranaka, Tetsuhito, et al.
Publicado: (2016)

Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study
por: Kim, Mi-Jung, et al.
Publicado: (2008)

Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?
por: Knikman, Jonathan E., et al.
Publicado: (2020)

A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer
por: Ikeda, M, et al.
Publicado: (2002)

Fluoropyrimidine-induced cardiotoxicity
por: Deac, Andrada Larisa, et al.
Publicado: (2020)

Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study
por: ZHU, Lucheng, et al.
Publicado: (2021)

Phase I study of oral S-1 and concurrent radiotherapy in patients with head and neck cancer
por: Nakata, Kensei, et al.
Publicado: (2013)

Fluoropyrimidine combination therapy versus fluoropyrimidine monotherapy for gemcitabine-refractory advanced pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials
por: Tian, Wei, et al.
Publicado: (2023)

Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer
por: Oki, Yasunari, et al.
Publicado: (2010)

Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer
por: Leonard, R C F
Publicado: (2001)

Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation
por: Milano, G, et al.
Publicado: (2004)

Effect of visual feedback during laparoscopic basic training using a box trainer with a transparent top
por: Maemura, Kosei, et al.
Publicado: (2017)

Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer
por: Kerner, Gerald SMA, et al.
Publicado: (2014)

Upfront DPYD Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress
por: Desilets, Antoine, et al.
Publicado: (2022)

Phase 2 Multi-institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma
por: Herman, Joseph M, et al.
Publicado: (2015)

Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small-cell lung cancer: a Phase II trial
por: Martínez, Enrique, et al.
Publicado: (2016)

Feasibility and Safety of Repeated Carbon Ion Radiotherapy for Locally Advanced Unresectable Pancreatic Cancer
por: Okamoto, Masahiko, et al.
Publicado: (2021)

Competing Risk Analysis of Outcomes of Unresectable Pancreatic Cancer Patients Undergoing Definitive Radiotherapy
por: Chen, Yi-Lun, et al.
Publicado: (2022)

Survival Benefits of Small Anatomical Resection of the Liver for Patients with Hepatocellular Carcinoma and Impaired Liver Function, Based on New-Era Imaging Studies
por: Sakoda, Masahiko, et al.
Publicado: (2016)

Oral Tegafur-Uracil Combination plus Leucovorin versus Other Fluoropyrimidine Agents in Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Kataria, Satya Pal, et al.
Publicado: (2022)

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
por: Elganainy, Dalia, et al.
Publicado: (2018)

Phase II Trial of Concurrent Sunitinib and Image-Guided Radiotherapy for Oligometastases
por: Tong, Charles C. L., et al.
Publicado: (2012)

Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines
por: Shiga, Taro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_en28eqr7o72fnsvvrrtu6r4u4b